UNITY Biotechnology Reports Granting of New Employment Inducement Awards
24 févr. 2021 08h00 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
Study published in Cell Metabolism Reveals New Therapeutic Approach Aimed at Restoring Vascular Health and Reversing Age-Related Eye Disease
08 févr. 2021 08h00 HE
|
Unity Biotechnology, Inc.
Study shows that senescent cells accumulate in the eye of patients with diabetic retinopathy, and elimination of these cells in preclinical models ameliorates disease Researchers at UNITY...
UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
01 févr. 2021 08h00 HE
|
Unity Biotechnology, Inc.
Mike Sapieha brings world-class expertise in aging-related ophthalmologic and neurologic diseases UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz,...
UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O’Neill, M.B., to the Board of Directors
14 déc. 2020 07h00 HE
|
Unity Biotechnology, Inc.
Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY’s Board Changes Reflect Strategic Focus on Clinical Development in Age-Related Diseases of the Eye and Brain ...
UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates
04 nov. 2020 16h01 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema
12 oct. 2020 08h00 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
15 sept. 2020 08h00 HE
|
Unity Biotechnology, Inc.
- Corporate restructuring to extend cash runway through mid-2022 and key milestones - - UBX1325 to enter clinical development in patients with diabetic macular edema - SAN FRANCISCO, Calif., Sept. ...
UNITY Biotechnology to Participate in Upcoming September Investor Conferences
04 sept. 2020 08h00 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
UNITY Biotechnology Announces Appointment of Lynne Sullivan as Chief Financial Officer
31 août 2020 16h05 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital
04 août 2020 16h05 HE
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...